AAV9 vector-based IGHMBP2 gene therapy(Alcyone Therapeutics)

N/A

Report date: 2024/07/18 17:33:14

Base Information

Drug NameAAV9 vector-based IGHMBP2 gene therapy(Alcyone Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV9 vector
Mechanisms of ActionDNA-binding protein SMUBP-2 modulators
TargetsDNA-binding protein SMUBP-2
Therapy Area/IndicationsCharcot-Marie-Tooth 1BCharcot-Marie-Tooth Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAlcyone Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAlcyone Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCharcot-Marie-Tooth 1BCharcot-Marie-Tooth Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A